William Blair analyst Matt Larew initiated coverage of Bio-Techne with an Outperform rating. The company is positioned to accelerate its above-market growth in cell and gene therapy through eventual ownership of Wilson Wolf, whose cell culture devices are used in more than 45% of all clinical C> trials, the analyst tells investors in a research note. The firm says Bio-Techne will provide both the “printer” and “ink” of C> trials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TECH: